The U.S. will likely emerge the winner in a "cold currency war" that is heating up, an expert said.Currenciesread more
These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
Tariffs are the only instrument left for addressing China's systematic and excessive surpluses on its U.S. trades, writes Michael Ivanovitch.US Economyread more
In its latest attempt to build market credibility, China on Monday launched the Science and Technology Innovation Board, or "STAR Market," on which 25 companies were listed.China Economyread more
When Cathy Hsu and Tony Hsieh wanted to build an English language app for Chinese children, they decided to follow Facebook and Google's lead.Start-upsread more
Stocks in Asia traded lower on Monday afternoon, as a Nasdaq-style technology board on the Shanghai Stock Exchange marked its debut.Asia Marketsread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
The firing of the tear gas was the latest confrontation between police and protesters who have taken to the streets for over a month to fight a proposed extradition bill and...China Politicsread more
Last week shows that oil prices are not the indicator for Middle East tensions they once were, and worries about global demand and growing U.S. production has changed that...Market Insiderread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Celgene was on the move in today's session following an upgrade to buy from neutral at BTIG.
The firm believes that Celgene is better positioned than many of its peers in the biotech space, and also that strong future sales will push the New Jersey-based company higher.
BTIG has a $138 price target on Celgene, which is a 19% upside from current levels.
Dane Leone – the analyst behind the call– joined the "Halftime Report" to discuss why this stock should be on your buy list.
Biotech has had a rough run for the past few decades, but Leone thinks the sector is now in the early stages of recovery.
And he believes Celgene is well-positioned to take advantage of the biotech bounce.
"We think Celgene is going to clearly be the leader in the sector in the next 12 months," he said on the "Halftime Report."